Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease

Thing, Mira; Werge, Mikkel Parsberg; Kimer, Nina; Hetland, Liv Eline; Rashu, Elias Badal; Nabilou, Puria; Junker, Anders Ellekaer; Galsgaard, Elisabeth Douglas; Bendtsen, Flemming; Laupsa-Borge, Johnny; McCann, Adrian; Gluud, Lise Lotte

doi:10.1186/s12876-024-03129-7

Cited by 5 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed higher plasma concentrations of propionate, formate, valerate, and αmethylbutyrate but lower plasma acetate concentrations in MASLD patients compared to healthy controls. Moreover, among MASLD patients, significant fibrosis was positively associated with several SCFAs [351].…”

Section: Metabolic Dysfunction-associated Steatotic Liver Diseasementioning

confidence: 88%

Short-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication

Facchin,

Bertin,

Bonazzi

et al. 2024

Preprint

View full text Add to dashboard Cite

The gastrointestinal tract is colonized by trillions of different microorganisms, named the gut microbiota, which is key to degrade undigested food such as dietary fibers. The fermentation of these food components leads to the production of short-chain fatty acids (SCFA) acetate, propionate, and butyrate, which exploit several beneficial roles for the host’s health. Their production and absorption happen in different ways in the human intestine and depend on the type of dietary fiber reaching the gut and the microorganisms involved in the fermentation. The supplementation of SCFAs, mostly butyrate, in treating gastrointestinal, metabolic, cardiovascular, and gut-brain-related diseases has been reported in the medical literature. This review aims to give an overview of the production and absorption dynamics of acetate, propionate, and butyrate in the human gut, with a final focus on the role played by these SCFAs on gastrointestinal and metabolic health and the present therapeutic implications.

show abstract

Section: Metabolic Dysfunction-associated Steatotic Liver Diseasementioning

confidence: 88%

Short-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication

Facchin,

Bertin,

Bonazzi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The results showed higher plasma concentrations of propionate, formate, valerate, and α-methylbutyrate but lower plasma acetate concentrations in MASLD patients compared to healthy controls. Moreover, among MASLD patients, significant fibrosis was positively associated with several SCFAs [335].…”

Section: Metabolic Dysfunction-associated Steatotic Liver Diseasementioning

confidence: 88%

Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications

Facchin,

Bertin,

Bonazzi

et al. 2024

Life

View full text Add to dashboard Cite

The gastrointestinal tract is home to trillions of diverse microorganisms collectively known as the gut microbiota, which play a pivotal role in breaking down undigested foods, such as dietary fibers. Through the fermentation of these food components, short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate are produced, offering numerous health benefits to the host. The production and absorption of these SCFAs occur through various mechanisms within the human intestine, contingent upon the types of dietary fibers reaching the gut and the specific microorganisms engaged in fermentation. Medical literature extensively documents the supplementation of SCFAs, particularly butyrate, in the treatment of gastrointestinal, metabolic, cardiovascular, and gut-brain-related disorders. This review seeks to provide an overview of the dynamics involved in the production and absorption of acetate, propionate, and butyrate within the human gut. Additionally, it will focus on the pivotal roles these SCFAs play in promoting gastrointestinal and metabolic health, as well as their current therapeutic implications.

show abstract

“…The frozen stool samples were analyzed by gas chromatography-tandem mass spectrometry (Novogene, Beijing, China) to measure SCFA levels. Sample collection and pretreatment, standard preparation, peak detection, and data analysis were performed as per the protocols [ 27 , 28 ].…”

Section: Methodsmentioning

confidence: 99%

Pretreatment with an antibiotics cocktail enhances the protective effect of probiotics by regulating SCFA metabolism and Th1/Th2/Th17 cell immune responses

Xu,

Guo

et al. 2024

BMC Microbiol

View full text Add to dashboard Cite

Background Probiotics are a potentially effective therapy for inflammatory bowel disease (IBD); IBD is linked to impaired gut microbiota and intestinal immunity. However, the utilization of an antibiotic cocktail (Abx) prior to the probiotic intervention remains controversial. This study aims to identify the effect of Abx pretreatment from dextran sulfate sodium (DSS)-induced colitis and to evaluate whether Abx pretreatment has an enhanced effect on the protection of Clostridium butyricum Miyairi588 (CBM) from colitis. Results The inflammation, dysbiosis, and dysfunction of gut microbiota as well as T cell response were both enhanced by Abx pretreatment. Additionally, CBM significantly alleviated the DSS-induced colitis and impaired gut epithelial barrier, and Abx pretreatment could enhance these protective effects. Furthermore, CBM increased the benefit bacteria abundance and short-chain fatty acids (SCFAs) level with Abx pretreatment. CBM intervention after Abx pretreatment regulated the imbalance of cytokines and transcription factors, which corresponded to lower infiltration of Th1 and Th17 cells, and increased Th2 cells. Conclusions Abx pretreatment reinforced the function of CBM in ameliorating inflammation and barrier damage by increasing beneficial taxa, eliminating pathogens, and inducing a protective Th2 cell response. This study reveals a link between Abx pretreatment, microbiota, and immune response changes in colitis, which provides a reference for the further application of Abx pretreatment before microbiota-based intervention.

show abstract

Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease

Cited by 5 publications

References 34 publications

Short-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication

Short-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication

Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications

Pretreatment with an antibiotics cocktail enhances the protective effect of probiotics by regulating SCFA metabolism and Th1/Th2/Th17 cell immune responses

Contact Info

Product

Resources

About